FRACTYL HEALTH, INC.
GUTSFractyl Health is a Burlington, Massachusetts-based healthcare company focused on metabolic diseases like obesity and type 2 diabetes. The company developed Revita, an outpatient endoscopic procedure to modify duodenal dysfunction, and Rejuva, a gene therapy platform in preclinical development to enable the pancreas to produce glucagon-like peptide-1 (GLP-1).
Drugs in Pipeline
0
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
GUTS Earnings Report
EPS Est: $-0.15 | FQ end 2026-06
No drugs found in this phase.
Full breakdown — the signals behind the verdict
Frequently asked questions
When is FRACTYL HEALTH, INC.'s next FDA catalyst?→
FRACTYL HEALTH, INC.'s (GUTS) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GUTS biotech catalysts?→
Add GUTS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow FRACTYL HEALTH, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.